STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.

Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.

Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.

Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.

Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.

Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.

Rhea-AI Summary
Abbott is working to expand access to its continuous glucose monitoring technology for people with diabetes. The FreeStyle Libre system eliminates routine fingersticks and provides real-time access to glucose numbers. Abbott has already improved the lives of over 5 million people with diabetes, but there is still a large population that could benefit from the technology. Medicare in the US and the French health authorities have expanded coverage for Abbott's technology, and other countries are following suit. Abbott is focused on making its technology accessible and affordable to as many people as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Summary
Fortune honors Abbott for groundbreaking Freedom 2 Save program, promoting financial wellness for employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
Rhea-AI Summary
Abbott reports Q3 2023 financial results with sales of $10.1 billion. Organic sales growth for underlying base business is 13.8%. Full-year 2023 EPS guidance range narrowed. Abbott acquires Bigfoot Biomedical and expands collaboration with mAbxience Holdings. Investments made during the pandemic drive broad-based growth. Abbott on track to deliver financial commitments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.71%
Tags
Rhea-AI Summary
Abbott to announce Q3 2023 financial results on Oct. 18 before market opens. Earnings conference call at 8am Central time. Webcast accessible through Abbott's Investor Relations website. Archived edition of the call available later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
-
Rhea-AI Summary
Abbott releases 2022 Global Sustainability Report, highlighting efforts to improve access and affordability of life-saving technologies. They introduced new health technologies at lower prices, reduced emissions, and achieved zero waste at 6 sites. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
Rhea-AI Summary
Abbott completes acquisition of Bigfoot Biomedical, expanding presence in diabetes care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Rhea-AI Summary
Abbott declares quarterly dividend of 51 cents per share, marking the 399th consecutive quarterly dividend since 1924. Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
dividends
-
Rhea-AI Summary
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East, and Africa. First molecules expected to launch in 2025. Collaboration expands Abbott's medicines offering and provides access to affordable biosimilar medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
-
Rhea-AI Summary
Abbott and WeightWatchers announce a connected app to help people with diabetes understand how food and activity impact glucose levels. WeightWatchers members can now access glucose data from Abbott's FreeStyle Libre 2 system within the WW app. Maintaining a healthy weight is key to glucose control for people with Type 2 diabetes. Clinical data shows that healthy weight loss leads to a reduction in average glucose. The WW Diabetes-Tailored Plan has been proven to reduce hemoglobin A1c levels and decrease diabetes distress. New WW members can enjoy a free month of the WeightWatchers Diabetes-Tailored Plan and connect the WW app with the FreeStyle Libre 2 system. New FreeStyle Libre 2 users may be eligible for a free trial of the system. The FreeStyle Libre portfolio is the number one sensor-based glucose monitoring system in the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
Rhea-AI Summary
Abbott Pandemic Defense Coalition contributes to virus studies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none

FAQ

What is the current stock price of Abbott Laboratories (ABT)?

The current stock price of Abbott Laboratories (ABT) is $117.36 as of November 18, 2024.

What is the market cap of Abbott Laboratories (ABT)?

The market cap of Abbott Laboratories (ABT) is approximately 203.2B.

What does Abbott Laboratories specialize in?

Abbott Laboratories specializes in cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

What are some of Abbott’s recent product launches?

Recent product launches include the PROTALITY™ high-protein nutrition shake and the TriClip™ system for tricuspid valve repair.

How much of Abbott’s sales are generated outside the United States?

Approximately 60% of Abbott’s sales are generated outside the United States.

What is Abbott’s PROTALITY™ brand?

The PROTALITY™ brand is a high-protein nutrition shake designed to support weight loss while preserving muscle mass, addressing global health challenges like obesity.

How does Abbott support global health initiatives?

Abbott supports global health initiatives through strategic partnerships like their collaboration with the Real Madrid Foundation to reduce childhood malnutrition and promote healthy habits.

What is Abbott’s financial performance like?

Abbott has demonstrated robust financial performance, with strong Q1 2024 results and a consistent track record of dividend payouts, evidenced by its inclusion in the S&P 500 Dividend Aristocrats Index.

How many employees does Abbott have?

Abbott employs over 114,000 people worldwide.

Which continuous glucose monitoring system is Abbott known for?

Abbott is known for its FreeStyle Libre continuous glucose monitoring systems, which are widely recognized for their innovation in diabetes management.

What is Abbott's mission?

Abbott's mission is to help people live more fully at all stages of life by developing life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines.

In how many countries does Abbott operate?

Abbott operates in more than 160 countries worldwide.

Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

203.19B
1.73B
0.53%
78.64%
0.81%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ABBOTT PARK